Biotechnology major Biocon has launched advanced novel therapy for the treatment of Hepatitis C at a low cost.
Biotechnology major Biocon has launched advanced novel therapy for the treatment of Hepatitis C at a low cost.
CIMIVIR-L, a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, will be made available to patients in India at a fraction of the global cost of the innovator brand, Biocon Ltd said in a statement.
The cost of a 12-week course of this combination therapy in the US is $94,500 (about Rs 63 lakh). Biocon, President-Marketing, Ravi Limaye said the introduction of CIMIVIR-LTM will strengthen the company's current portfolio of virology products.
"It furthers our commitment to offer affordable therapy for unmet patient needs in debilitating and life-threatening conditions," he added.
CIMIVIR-L is an equivalent of the innovator product commercialised by Gilead Sciences in the US.
Biocon had entered into a licensing agreement last year with US-based Gilead to manufacture and commercialise its chronic Hepatitis-C blockbuster product range, Sofosbuvir and Sofosbuvir-Ledipasvir combination in India and in select emerging markets.
These territories account for more than 50% of the global Hepatitis C prevalence.
The Drugs Controller General of India (DCGI) recently approved the sale of Sofosbuvir-Ledipasvir combination, which is being manufactured in India under a license from Gilead.
CIMIVIR-L, a once-a-day oral therapy, will offer a convenient, effective and safe alternative to people infected with the Hepatitis-C virus (HCV).
It is estimated that nearly one lakh people die annually in India from HCV infection and co-morbidities.
CIMIVIR-L is indicated for Hepatitis-C Genotype 1 patients who account for 25% of the total estimated HCV patient population of 18 million in the country.
Biocon stock was trading at Rs 507.20, up 5.28%, on the BSE.
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
 "Representational image")
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
)
){kind=small}
){kind=small}
)
)
)
)
)
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}